Faculty

Back to Index
Araz Marachelian, MD
Assistant Professor of Clinical Pediatrics
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 8573

Awards

NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)

Southern California Super Doctors

Pasadena Magazine: Top Doctor, 2013

Southern California Super Doctors

AACR/ASCO: Clinical Trial Training Workshop Award, 2005

University of California, Irvine: Outstanding Achievement in Pediatrics and Psychiatry, 1999

University of California, Berkeley: High Distinction of Honors, 1995

University of California, Berkeley: Outstanding Service Award, 1995

Undergraduate Research Award National Science Foundation

Publications

The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs. 2017 Jan 01; 1043454216680595. View in: PubMed

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 Oct; 66:144-52. View in: PubMed

A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 Aug; 63(8):1349-56. View in: PubMed

The clinical management and outcomes of cervical neuroblastic tumors. J Surg Res. 2016 Jul; 204(1):109-13. View in: PubMed

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75. View in: PubMed

Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With (131) I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42. View in: PubMed

Comparative pharmacokinetics, safety, and tolerability of two sources of ch14. 18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. View in: PubMed

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. View in: PubMed

(131)I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015 Apr; 21(4):673-81. View in: PubMed

Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatr Hematol Oncol. 2015 Feb; 32(1):26-31. View in: PubMed

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014; 7(1):256. View in: PubMed

Infectious complications in the first year following autologous hematopoietic progenitor cell rescue for children with brain tumors. Pediatr Blood Cancer. 2013 Dec; 60(12):2012-7. View in: PubMed

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer. 2013 Nov; 60(11):1801-8. View in: PubMed

Forearm skeletal muscle neuroblastoma in a child: a rare primary location. J Pediatr Hematol Oncol. 2013 Jan; 35(1):61-3. View in: PubMed

The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer. 2012 May; 58(5):675-81. View in: PubMed

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 1; 18(9):2679-86. View in: PubMed

A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. View in: PubMed

Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation. Pediatr Blood Cancer. 2010 Jul 15; 55(1):42-6. View in: PubMed

Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex. Pediatr Blood Cancer. 2010 Jan; 54(1):170-2. View in: PubMed

High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer. 2009 Jul 1; 115(13):2956-63. View in: PubMed

Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplant. 2008 Jan; 41(2):167-72. View in: PubMed

Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Jul; 45(1):37-42. View in: PubMed

Impact of human endogenous retroviral elements on cellular genes: strategy for isolation of LTR-driven chimeric transcripts. Leukemia. 1999 Apr; 13 Suppl 1:S97-8. View in: PubMed

Powered bySC CTSI